<DOC>
	<DOCNO>NCT00111514</DOCNO>
	<brief_summary>The purpose study evaluate safety Leish-111f + MPL-SE vaccine give three injection every 28 day three dose level Leish-111f protein , combination standard pentavalent antimony therapy adult patient mucosal leishmaniasis .</brief_summary>
	<brief_title>Study Evaluate Leish-111F + MPL-SE Vaccine Treatment Mucosal Leishmaniasis</brief_title>
	<detailed_description>Mucosal leishmaniasis disfigure possibly fatal infection . All available medical therapy require week treatment cause significant toxicity . In Peru , standard therapy daily intravenous ( IV ) pentavalent antimony ( 20 mg/kg/day ) 28 day . It appear Leishmania infection eliminate T helper 1 immune response . These finding argue vaccine augments mucosal leishmaniasis patient ’ T helper 1 response eliminate infection disease . This study phase 1 , randomize , double-blind , placebo control , sequential dose-escalating trial evaluate safety immunogenicity three injection 5 , 10 , 20 μg Leish-111f protein + 25 μg MPL-SE adjuvant give 4 week interval adjunct standard chemotherapy pentavalent antimony ( 20 mg/kg/day 28 day ) patient mucosal leishmaniasis .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Mucocutaneous</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patients mucosal leishmaniasis confirm positive smear , vitro culture PCR test Mucosal leishmaniasis must involve vocal cord cause respiratory distress , must evidence disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Leishmaniasis</keyword>
	<keyword>Subunit vaccine</keyword>
	<keyword>therapeutic</keyword>
	<keyword>T-cell</keyword>
	<keyword>pentavalent antimony</keyword>
</DOC>